NERLYNX Drug Patent Profile

Which patents cover Nerlynx, and what generic alternatives are available?

Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NERLYNX is neratinib maleate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nerlynx

Nerlynx was eligible for patent challenges on July 17, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2030. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (neratinib maleate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NERLYNX

US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	23
Patent Applications:	4,929
Drug Prices:	Drug price information for NERLYNX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NERLYNX
What excipients (inactive ingredients) are in NERLYNX?	NERLYNX excipients list
DailyMed Link:	NERLYNX at DailyMed

See drug prices for NERLYNX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NERLYNX

NDA:

208051

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NERLYNX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 2
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
National Comprehensive Cancer Network	Phase 2

See all NERLYNX clinical trials

Pharmacology for NERLYNX

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for NERLYNX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NERLYNX	Tablets	neratinib maleate	40 mg	208051	1	2021-07-19

US Patents and Regulatory Information for NERLYNX

NERLYNX is protected by twenty US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y	Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes

Expired US Patents for NERLYNX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017

International Patents for NERLYNX

See the table below for patents covering NERLYNX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	068932
Argentina	103866
Australia	2008312474
Brazil	122019023745
Brazil	PI0818464

Supplementary Protection Certificates for NERLYNX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3000467	301237	Netherlands		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180904
3000467	PA2023520	Lithuania		PRODUCT NAME: NERATINIBAS; REGISTRATION NO/DATE: EU/1/18/1311 20230526
3000467	LUC00310	Luxembourg		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	CA 2023 00021	Denmark		PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180904
3000467	2023C/527	Belgium		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904

NERLYNX (neratinib): Market Dynamics and Financial Trajectory (US and key ex-US markets)

Last updated: July 30, 2026

Executive summary: Nerlynx (neratinib) has shifted from an early-growth pipeline product to a mature, label-constrained oncology asset. Its revenue path is driven by (1) HER2-positive breast cancer treatment placement after adjuvant trastuzumab, (2) switching from the historically dominant “expanded” use cases toward breast cancer subpopulations and evolving sequencing, (3) payer and hospital pathway tightening for oral HER2 TKIs, and (4) competitive pressure from newer HER2 therapies and standard-of-care sequence changes. Financial trajectory has been shaped by rapid category uptake early, then a slowdown as the adjuvant opportunity matured and prescriber adoption plateaued, while utilization growth in metastatic settings remained more sensitive to sequencing and to toxicity-related adherence issues typical for neratinib-based regimens.

---

What is Nerlynx (neratinib) approved for and how does label scope drive demand?

Featured answer: Nerlynx is an oral HER2 kinase inhibitor used in HER2-positive breast cancer, with the largest commercial footprint historically tied to the extended adjuvant setting after trastuzumab. Demand is primarily label-and-sequencing dependent: where neratinib sits in treatment algorithms determines patient counts, dosing adherence, and payer acceptance.

Key clinical use cases that affect market penetration

Nerlynx demand is anchored in two types of utilization models:

1. Adjuvant extended therapy (post-trastuzumab)

   • Largest early adoption lever.
   • Commercial outcome depends on eligible patient share of HER2+ early breast cancer, completion rates of adjuvant trastuzumab, and payer coverage.

2. Metastatic HER2-positive breast cancer in combination regimens

   • Utility is more sensitive to regimen selection and line of therapy.
   • Growth depends on whether oncologists choose neratinib combinations over competing HER2 standards.

Dosing and adherence dynamics that impact net sales

Neratinib is an oral drug with diarrhea being a primary limiting toxicity. Real-world uptake and persistence depend on:

• prophylactic anti-diarrheal protocols used in practice,
• patient ability to tolerate dose levels,
• payer support for supportive care and adherence.

Those factors translate into “effective demand,” not just prescribed demand.

---

How has Nerlynx revenue evolved and what financial trajectory does the market imply?

Featured answer: Nerlynx revenue growth followed a typical adoption curve: early uptake led to a peak period as prescribers established the adjuvant place in therapy; subsequent years show slower growth as the eligible population matured, payer restrictions increased, and HER2 treatment algorithms evolved. The trajectory is consistent with a mature oral oncology franchise where marginal volume depends on expanding eligible patient share and improving persistence.

Revenue drivers by commercial stage

Phase 1: launch and early adoption

• Fastest uptake occurs after label clarity and guideline integration.
• Commercial teams focus on oncologists treating HER2+ early breast cancer who complete trastuzumab.

Phase 2: maturation

• Prescriber base becomes stable.
• Growth becomes dependent on incremental conversions from competing options and tightening toxicity management outcomes.

Phase 3: plateau risk

• Competition from newer HER2 agents alters sequencing.
• If payer policies become more restrictive for marginal benefit patients, volume declines or shifts to fewer regimens.

What to watch in ongoing financials

Market analysts generally track these leading indicators for neratinib:

• prescriptions and treatment starts (not just total script counts),
• persistence and discontinuation rates after first months,
• payer coverage breadth by plan type (commercial vs Medicare Advantage),
• ordering patterns by specialty centers that treat HER2+ early breast cancer at higher volumes.

---

What patents protect Nerlynx and how do they affect market timing and competition?

Featured answer: Nerlynx has a layered patent estate spanning active ingredient, pharmaceutical compositions, and method-of-use claims. Patent expiry and exclusivity timing, plus regulatory exclusivity, determine when ANDA-style generic options or biosimilar-style competition could occur. For a small-molecule oral cancer drug like neratinib, generic and follow-on entry risk is primarily controlled by composition and method-of-use patent barriers and by the ability to design around claims.

Patent estate components that typically govern “when competition starts”

For neratinib commercialization, risk typically clusters into:

• drug substance patents (core molecule coverage),
• drug product patents (formulation, stability, dosing),
• method-of-use patents (specific indications, sequencing, or combinations),
• process/manufacturing patents (less common as primary barriers but relevant in litigation leverage).

How method-of-use patents shape generic launch scenarios

Even if composition patents expire, generic entry may still be delayed for specific claims tied to:

• extended adjuvant therapy after trastuzumab,
• particular combination regimens in metastatic HER2+ settings,
• defined dosing schedules or patient subsets.

For courts, the key issue becomes whether a generic label “carves out” protected methods or whether the product is expected to induce infringement under US theory.

---

When does Nerlynx lose exclusivity and what are the generic entry risks?

Featured answer: Nerlynx exclusivity loss is staged: composition and method-of-use patent expirations and any regulatory exclusivity windows determine the earliest lawful label and marketing timing for generic competition. Generic entry risk is highest when the patent landscape shifts from exclusive coverage to carve-out feasibility and when ANDA filers can avoid non-infringement or secure settlements.

Paragraph IV challenges and settlement-driven entry

For branded oncology molecules with layered patents, generic entrants often use:

• Paragraph IV certifications to challenge one or more listed patents,
• litigation to negotiate “at-risk” entry versus settlement dates.

The practical result is often a negotiated launch window tied to dismissal, claim narrowing, or US launch authorization after certain dates.

Label and carve-out risk in practice

For neratinib, the most commercially valuable indications are also those most likely to have method-of-use protection. A generic product that launches with narrower label restrictions can still generate revenue, but it usually captures less share than the full-label branded competitor.

---

What is the Orange Book status of Nerlynx (neratinib) and how many patents are listed?

Featured answer: Orange Book listings for neratinib include multiple patent entries that typically cover drug substance, composition/formulation, and method-of-use. The count and status of those entries determine the number of potential Paragraph IV triggers and the complexity of generic carve-outs.

How to interpret Orange Book listings for litigation and launch models

Use three metrics:

1. Number of listed patents by expiry date
2. Which patents are “important” for each FDA-approved indication
3. Whether patents are method-of-use versus formulation/composition

These metrics drive:

• probability of litigation,
• length of potential delay,
• likely settlement structures (early carve-out launch versus delayed full indication launch).

---

What patent litigation affects Nerlynx market entry and licensing deals?

Featured answer: Nerlynx’s competitive timeline depends on whether ANDA filers or other generic applicants challenge specific Orange Book patents, and on whether parties settle for a delayed entry date or licensing-based arrangement. For branded small-molecule oncology products, litigation often results in either:

• delayed entry with limited early launch, or
• design-around and label carve-outs that reduce the challenger’s addressable market.

How litigation posture impacts commercial pricing

If launch is uncertain, payers and providers tend to wait on contract repricing. If entry is likely, branded companies sometimes:

• defend coverage through rebate restructuring,
• expand patient support,
• negotiate formulary positioning to protect share.

---

How does Nerlynx compare with competing HER2 therapies and what does that do to market share?

Featured answer: Nerlynx sits within the HER2-positive breast cancer standard-of-care, competing with other HER2-targeted agents across adjuvant and metastatic settings. Market share is sensitive to where oncologists place neratinib in sequencing, to tolerability and patient eligibility, and to payer pathway design.

Competition dynamics that typically pressure neratinib

• Treatment sequencing changes: Newer HER2 regimens can reallocate eligible patients away from extended TKI use.
• Line-of-therapy effects: If neratinib’s role shifts to later lines, early utilization slows.
• Access and prior authorization: Oral oncolytics with toxicity management often face more restrictive coverage criteria.

Why tox-related adherence matters commercially

Even with favorable efficacy, diarrhea and adherence challenges reduce effective use. Competitors with easier tolerance profiles often expand earlier in the care pathway.

---

What regulatory milestones and FDA pathway status shape commercialization and switching?

Featured answer: FDA-approved status determines labeling and prescriber trust, while post-approval label expansions affect addressable patient populations. Market dynamics then shift based on whether new indications gain uptake and whether subsequent safety information influences payer policies.

Regulatory signals that move utilization

Track:

• label expansions that broaden metastatic or combination eligibility,
• safety communications that affect tolerability protocols,
• any updates to dosing guidance that improve real-world persistence.

---

How do payers and formularies affect Nerlynx net price and volume?

Featured answer: Nerlynx net sales are a function of both unit demand and net pricing after rebates. Commercial volume depends on formulary access in oncology-heavy plans, while net price depends on contract terms that typically change as competition and generic risk rise.

Key payer mechanics

• Formulary tier placement: Higher tiers reduce scripts.
• Prior authorization and step therapy: Delays reduce starts and persistence.
• Rebate structure: As the product matures, rebate pressure often increases as formulary negotiations intensify.

---

Which regions matter most for Nerlynx and how does geography change the revenue picture?

Featured answer: Nerlynx’s financial trajectory is shaped by US economics first, then by ex-US adoption where HER2 treatment pathways, reimbursement generosity, and competitive landscapes differ. Countries with stronger reimbursement for oncology TKIs support steadier demand; markets with more restrictive reimbursement shift utilization to competing regimens.

Ex-US adoption variables

• national HER2 treatment guidelines and reimbursement rules,
• availability of prophylactic diarrhea management protocols,
• competitive intensity from local and global HER2 brands.

---

What formulation or manufacturing IP barriers exist for Nerlynx generics?

Featured answer: Beyond core composition and method-of-use claims, formulation and process patents can block generic product development by adding constraints around drug release, stability, or manufacturability. For an oral molecule like neratinib, these barriers can affect “design-around” feasibility and increase litigation leverage.

How manufacturing IP can slow “at-risk” launches

Generic applicants may still launch at risk if they can:

• meet bioequivalence with a non-infringing product,
• clear manufacturing process constraints,
• avoid protected formulation and stability claims.

When manufacturing patents are asserted, settlements often include specific product design requirements.

---

How strong is the patent estate for Nerlynx and what does it mean for long-term exclusivity?

Featured answer: Nerlynx’s patent estate is typically assessed as “layered,” with multiple active patents spanning different claim categories. A layered estate prolongs exclusivity against full generic entry and increases the likelihood of ongoing litigation or carve-out strategies.

Patent strength indicators used in competitive modeling

• number of active Orange Book patents,
• recency of renewals,
• distribution of expiry dates across years (extension of last-to-expire),
• frequency and aggressiveness of litigation by the brand holder.

---

Key Takeaways

• Nerlynx demand is concentrated in HER2-positive breast cancer, with extended adjuvant use after trastuzumab historically providing the largest commercial anchor.
• The financial trajectory follows a typical mature-oncology pattern: early adoption, then slower growth as the eligible population matures and sequencing shifts.
• Net sales are driven as much by payer coverage and toxicity-adherence realities as by clinical indication scope.
• Competitive risk is shaped by a layered patent estate covering composition and method-of-use, which can delay full generic entry and enable label carve-outs.
• Litigation timing and settlement structures are central to when generic competition becomes economically meaningful.

---

FAQs

1) What factors determine Nerlynx uptake after trastuzumab in real-world practice?
Patient eligibility, diarrhea prophylaxis adherence, dosing tolerance, and prior authorization friction.

2) Does Nerlynx’s metastatic HER2 combination usage drive meaningfully different revenue risk than adjuvant use?
Yes, because metastatic sequencing and payer restriction dynamics are more line-dependent and more sensitive to competitor positioning.

3) How do net pricing and rebates typically evolve for an oral oncology drug like neratinib as it matures?
Net price pressure increases with formulary negotiations and the growing probability of future competition.

4) What generic launch scenario is most commercially damaging to Nerlynx?
A full-label generic entry for the largest protected indications that avoids meaningful carve-outs.

5) Why can patent method-of-use claims matter even if a generic clears composition patents?
Because the generic may still face restrictions through infringement theories tied to practice of the protected methods under the FDA label and likely prescribing behavior.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. Nerlynx (neratinib) Prescribing Information. US Food and Drug Administration.
3. FDA. Drug Approval Package: Nerlynx (neratinib). US Food and Drug Administration.

DrugChatter Q&A for NERLYNX

Nerlynx australia?